Demand for High Potency Active Pharmaceutical Ingredients Increases Due to High Prevalence of Cancer

 

High Potency Active Pharmaceutical Ingredients

High Potency Active Pharmaceutical Ingredients, also commonly known as HPAPIs, are pharmacologically active substances that exhibit biological activity at extremely low concentrations. These ingredients have therapeutic and prescriptive qualities that can be used to manufacture several drugs. Highly potent drugs represent a growing proportion of medicines, including therapies in development and those commercially available. HPAPIs are usually derived from plants or animals, depending on the nature of the drug. Their main function is to act as antioxidants, inhibitors, solubilizers, carriers and surfactants. These are required to generate effective active materials for various applications in pharmaceuticals.

Highly potent APIs elicit a biological response at a very low dose. Traditional examples of HPAPIs are cytotoxic compounds and sex hormones such as estrogen. The demand for High Potency Active Pharmaceutical Ingredients is increasing worldwide due to high prevalence of cancer. For instance, according to the American Cancer Society, in 2019, there will be an estimated 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the U.S. Thus, various companies are focused on expanding their manufacturing capacities. In July 2021, Piramal Pharma Solutions announced its plans to expand its operations in Riverview with a US$ 35 million investment. According to the company, the expansion is expected to address increasing demand for drug substances, including high potency active pharmaceutical ingredients.

Pharmaceutical companies generally do not outsource manufacture of High Potency Active Pharmaceutical Ingredients as there is a risk of patent infringement and opt captive or in-house manufacturing. However, in the recent past, several factors have prompted companies to opt for outsourcing. A major factor is expansion strategies of pharmaceutical companies that are focused on expanding the geographical boundaries of the company. Moreover, increasing coat of R&D of new drugs and developing regulatory and legal framework has added to the financial burden. In such scenarios, pharmaceutical companies are increasing opting for outsourcing in the manufacturing of HPAPIs.

Comments

Popular posts from this blog

Air Purifier works as a Sanitizer in the air which helps in reducing pollutants, allergens, and toxins

Polyethylene Terephthalate Is A Non-Toxic Plastic, Mostly Used For Manufacturing Medical Devices

With the use of High-Frequency alternating current, Radiofrequency Ablation Device convert Electromagnetic Energy into Heat Energy